GLOSTRUP, DENMARK--(Marketwire - Mar 4, 2013) - Dako, an Agilent Technologies Company and worldwide provider of cancer diagnostics, unveiled the newest addition to its IHC portfolio at the 2013 USCAP congress in Baltimore, Md., today. As the exclusive Platinum Sponsor of the congress, Dako used the opportunity to present its new advanced staining solution to a global gathering of pathologists and lab personnel.

The solution, Dako Omnis, comprises hardware, software and reagents. It automates both IHC and ISH processes, meaning entire patient cases can be processed simultaneously. This allows pathologists to make quicker, more informed diagnoses. Oncologists can in turn prescribe relevant therapy with less anxiety-ridden waiting time for patients. 

"This solution provides a breakthrough in addressing some of the hitherto unmet needs in the anatomic pathology lab," said Dr. Pedro L. Fernandez of the Hospital Clinic and University of Barcelona, Spain. "Dako adopted a collaborative approach to bring this solution to market and cooperated with a global panel of key independent laboratory personnel. For over three years, we have been involved in the design and development of this solution. Dako has really listened and responded to the needs of the customer."

"Our customers tell us they are constantly expected to navigate fluctuating slide numbers with fewer qualified staff and mounting pressure to provide slides quickly in order to speed diagnosis," said Lisa Miller, corporate vice president of Global Commercial Business, Dako.

"With continuous loading, batch loading and overnight run options all available, Dako Omnis sets new standards for what customers can expect from an automated platform in terms of flexibility, capacity, efficiency and traceability of slides," she added.

Dako Omnis provides state-of-the-art software to bring lab control to a new level. Now, key processes such as slide processing and instrument maintenance can be traced to individual operators, greatly increasing quality control.

As with all Dako's instruments, customers can use the Dako Link software to connect all solutions and workstations to the laboratory's own information system. This approach gives the lab manager even more control over the processing of each individual slide that enters the lab.

Dako Omnis will be offered as part of Dako's current IHC portfolio, which includes the Autostainer Link 48 instrument, which Dako will continue to supply and support.

"Each pathology lab is different, and we believe with the addition of Dako Omnis to our current IHC offering, Dako has an even greater capability to bring the right solution to the right customer at the right time," said Miller. "Dako has a reputation for bringing firsts to market, with an unwavering passion for providing quality solutions. This enables us to offer our customers efficiency, choice and more time to ultimately provide better patient care. Advancing pathology is at the heart of what we do, and our customers tell us our new platform is an important addition."

About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at [ www.dako.com ].  

About Agilent Technologies
Agilent Technologies Inc. (NYSE: [ A ]) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at [ www.agilent.com ].